Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2025)

Legend Biotech's Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $2.1 million for Q3 2025.

• Quarterly Depreciation & Amortization (CF) fell 9.87% year-over-year to $2.1 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $6.7 million (down 54.5% YoY) and the FY2024 annual result came in at $23.4 million, up 14.22% from the prior year.
• Depreciation & Amortization (CF) was $2.1 million for Q3 2025 at Legend Biotech, down from $2.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $6.8 million in Q4 2024 and bottomed at -$20000.0 in Q4 2021.
• A 5-year average of $2.8 million and a median of $2.7 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Peak annual rise in Depreciation & Amortization (CF) reached 12505.0% in 2022, while the deepest fall reached 38.93% in 2022.
• Legend Biotech's Depreciation & Amortization (CF) stood at -$20000.0 in 2021, then surged by 12505.0% to $2.5 million in 2022, then surged by 115.68% to $5.4 million in 2023, then advanced by 27.0% to $6.8 million in 2024, then plunged by 68.42% to $2.1 million in 2025.
• Business Quant data shows LEGN's Depreciation & Amortization (CF) at $2.1 million in Q3 2025, $2.3 million in Q2 2025, and $2.3 million in Q1 2025.